

Sascha Troschke-Meurer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5356118/publications.pdf>

Version: 2024-02-01

10
papers

179
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

301
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 690467. | 4.8 | 10 |
| 2 | Reduction of CD11b ⁺ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD ₂ antibody ch14.18/CHO. <i>OncImmunology</i> , 2020, 9, 1836768. | 4.6 | 6 |
| 3 | GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 577-585. | 2.9 | 18 |
| 4 | Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy. <i>Frontiers in Pediatrics</i> , 2020, 8, 582820. | 1.9 | 6 |
| 5 | Low CD4 ⁺ /CD25 ⁺ /CD127 ⁺ regulatory T cell- and high INF- γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. <i>OncImmunology</i> , 2019, 8, 1661194. | 4.6 | 14 |
| 6 | Inflammatory response and treatment tolerance of long-term infusion of the anti-GD ₂ antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26967. | 1.5 | 15 |
| 7 | Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice. <i>PLoS ONE</i> , 2018, 13, e0207320. | 2.5 | 5 |
| 8 | Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEX Phase 2 Trial. <i>Cancers</i> , 2018, 10, 387. | 3.7 | 13 |
| 9 | PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD ₂ antibody ch14.18/CHO. <i>OncImmunology</i> , 2017, 6, e1343775. | 4.6 | 53 |
| 10 | Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. <i>OncImmunology</i> , 2016, 5, e1235108. | 4.6 | 39 |